Why Seres Therapeutics Stock Is Soaring Today
Shares of Seres Therapeutics (NASDAQ: MCRB) were soaring 17.1% higher as of 3:09 p.m. EDT on Wednesday. The big gain came after the company announced that it has achieved its target enrollment of 300 participants in a phase 3 study evaluating SER-109 in treating recurrent C. difficile infection (rCDI).
Today's news provided a big catalyst for the biotech stock because it moves Seres one step closer to potentially filing for approval for SER-109. The U.S. Food and Drug Administration (FDA) is requiring Seres to show the safety of the experimental therapy in at least 300 participants with a 24-week follow-up before it can submit a Biologics License Application (BLA).
Image source: Getty Images.
Source Fool.com
